Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials

Molica, Stefano; Allsup, David

Abstract

Introduction: Chronic lymphocytic leukemia (CLL) management has witnessed a transformative shift with the advent of time-limited venetoclax and anti-CD20 monoclonal antibody (mAb) regimens, as exemplified by the groundbreaking MURANO and CLL14 trials. Area covered: This article delves into the long-term follow-up data of fixed duration (FD) venetoclax combined with anti-CD20 mAb across various lines of CLL therapy. The data discussed here, not yet available in current literature, was unveiled at the 23rd European Hematological Association (EHA) congress held in Frankfurt in June 2023. Expert opinion: Combinations of venetoclax with anti-CD20 mAbs represent a compelling therapeutic option due to their finite treatment duration and remarkable achievement of undetectable minimal residual disease (uMRD). This not only ensures more enduring responses but also presents a manageable toxicity profile that suits a broad spectrum of CLL patients, including those who are elderly or less medically fit. Importantly, the integration of venetoclax/anti-CD20 mAb FD regimens may diminish the likelihood of CLL patients developing target mutations. This, in turn, enhances the potential for eliciting secondary clinical responses upon retreatment with venetoclax. Additionally, from an economic perspective, the cost-effectiveness of targeted therapy may further advocate for the selection of FD therapy as a frontrunner in CLL treatment.

Citation

Molica, S., & Allsup, D. (2023). Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials. Expert Review of Anticancer Therapy, https://doi.org/10.1080/14737140.2023.2288899

• Journal Article Type: Article
• Acceptance Date: Nov 24, 2023
• Online Publication Date: Nov 28, 2023
• Publication Date: Nov 28, 2023
• Deposit Date: Dec 4, 2023
• Publicly Available Date: Dec 6, 2023
• Journal: Expert Review of Anticancer Therapy
• Print ISSN: 1473-7140
• Electronic ISSN: 1744-8328
• Publisher: Taylor and Francis
• Peer Reviewed: Peer Reviewed
• DOI: https://doi.org/10.1080/14737140.2023.2288899
• Keywords: CLL; Fixed-duration venetoclax; MURANO trial; CLL14 trial; Long-term follow-up
• Public URL: https://hull-repository.worktribe.com/output/4467114